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Introduction. This is the ﬁrst reported case of gastrointestinal symptoms associated with withdrawal after chronic use of this
substance. Case Presentation. A 51-year-old Caucasian woman was referred to a hospital with a 3-day history of nausea, vomiting,
diarrhea, and abdominal discomfort. She reported no sick family members or contact with anyone who was ill. She did report
smoking 3–5 cigarettes of the herb “Salvia” consistently for 3-4 months and quit approximately 48 hours before symptoms
appeared. Her use of the herb had been consistent; she smoked several cigarettes each day. Laboratory results were essentially
normal including the white blood cell count. She received symptomatic treatment and was released after one day. Discussion.
Salvinorin A, a kappa-opioid receptor agonist, is the major active ingredient of S. divinorum. The unique opioid properties of
this herb may explain its ability to cause changes in intestinal transit time. Conclusion. A 51-year-old woman possibly developed
gastrointestinal manifestations suggestive of withdrawal from Salvia divinorum after smoking the substance consistently for 3 to 4
months. The widespread use of this herb will make the potential for withdrawal syndromes more commonplace.
1.Introduction
Although its possession and use is currently illegal in more
than 13 nations and 15 United States (US) states, Salvia
divinorum use remains widespread [1]. In a 2008 survey, an
estimated1.8millionpeopleintheUShadtriedthisherb[2].
S. divinorum, a member of the mint family, is a commonly
abused herb because of its associated hallucinogenic eﬀects
[1,3–6].Useofthissubstancedatesbackseveralcenturiesfor
spiritual practices by the Mazatec Indians of Mexico [1, 3–
7]. Other names for this herb include “Diviner’s Sage” and
“Magic Mint.” Adolescents and young adults are particularly
attracted to S. divinorum because of its accessibility, legality
in some areas, pereception of relative safety, and lack of
detectability upon urine drug screening [3]. Inhalation of
S. divinorum is most commonly done by smoking the dried
leaves or leaf extracts. Other ways of administration include
inhalation via volatilization, or using tinctures for buccal
administration [1, 3, 5].
Salvinorin A, a kappa-opioid receptor agonist, has
been demonstrated to be the major active ingredient of
S. divinorum [1, 3–6]. Taken orally, Salvinorin A has a mild
eﬀect. It is only minimally absorbed through the mouth
whilemostisdegradedinthegastrointestinaltract[3].When
smoked, however, this compound’s eﬀects are much more
pronounced generating hallucinations within seconds that
may last from 30 minutes to over 2 hours depending on
the amount inhaled [4, 6]. Salvinorin A is currently the
most potent naturally occurring hallucinogen to be isolated
[4]. Due to its hallucinogenic eﬀects and lack of evidence
for medicinal purposes, nine other US states currently have
Salvia divinorum or Salvinorin A labeled as a Schedule
1 substance. As a Schedule 1 substance, this agent has
high potential for abuse, no proven medicinal use, and is
potentially unsafe [8].
The most commonly reported desired eﬀects of S. div-
inorum include the “trip,” laughter, happiness, separation
from body, relaxation, visual and auditory eﬀects, percep-
tual modiﬁcation, and pleasant after eﬀects [3, 5]. Loss
of consciousness has also been reported with this herb
[9]. Unpleasant after eﬀects include reports of tiredness,
heaviness of head, dizziness, physical exhaustion, and slowed2 Case Reports in Medicine
mental function [5]. However, a search of the medical
literature failed to reveal any case reports of a S. divinorum
withdrawal syndrome. We report a case of S. divinorum
withdrawal in a patient who presents to the emergency
department with gastrointestinal distress after discontinuing
use of cigarettes containing the herb. One previous series
of patients with exposures to Salvia divinorum included
one patient with gastrointestinal symptoms similar to those
presented in our case. To our knowledge, this is the ﬁrst case
report addressing S. divinorum withdrawal.
2.CaseReport
A 51-year-old Caucasian woman with hypertension, chronic
obstructive pulmonary disease, coronary artery disease,
hypothyroidism, and type 2 diabetes was referred to the
hospital in June 2010 following a clinic visit for nausea,
vomiting, diarrhea, and abdominal discomfort. Surgical
history includes a coronary artery bypass graft (CABG)
involving aortic and pulmonic valve replacements, hysterec-
tomy, cholecystectomy, and an appendectomy. The patient
reports smoking cigarettes (2 packs/day) and occasional
alcohol use, but reports no other comorbidities or previous
episodes involving these symptoms. She denies abdominal
pain associated with food or bowel movements, or any
melena, hematochezia, hematuria, or hemoptysis. Patient
reports eating nothing out of the ordinary at home and
not eating out during the time frame related to these
symptoms. Patient also denies any sick family members
or close contact with anyone reporting gastrointestinal
symptoms. She had no history of similar episodes. Routine
medications include metformin 1000mg tablet twice daily,
gabapentin 300mg capsule twice daily, aspirin 81mg tablet
daily, lisinopril 10mg tablet daily, albuterol nebulizers daily
as needed, and levothyroxine tablet of unknown dose.
Patient reports allergies to penicillin and codeine. She did
not provide information regarding her reaction to these
medications.
Three months prior to hospital admission, she reported
starting to smoke the herb “Salvia” or Salvia divinorum,
which she purchased at a local gas station. She reported
smoking the herb daily for relaxation purposes. She smoked
one or two cigarettes three times each day. Her current
symptoms appeared approximately 48 hours after discontin-
uationofthisproduct.Initially,thepatientwasnauseous,but
symptoms progressed to diarrhea, abdominal discomfort,
and vomiting over the 3 days following discontinuation.
Upon hospital admission, a physical examination and
laboratory work was completed. Her blood pressure was
159/109mmHg, heart rate of 76 beats per minute, respira-
tory rate of 20 breaths per minute, and a temperature of
97.9◦F. Patient appeared well-nourished and well-developed
with no abnormalities found. Abdomen was tender to
palpation but was not distended. She had no rebound
tendernessorguarding.Shewasalertandorientedtoperson,
place, and time. Patient weight was 106kg.
A complete blood count revealed a white blood cell
count of 8,000cells/mm3 (normal 4.3–10,000cells/mm3)
with no other abnormalities or signs of infection. Blood
chemistry revealed a fasting glucose of 118mg/dL (normal
70–110mg/dL) and blood urea nitrogen level of 6mg/dL
(normal 7–18mg/dL). All other levels measured were within
normal limits including serum creatinine of 0.91mg/dL
(normal 0.6–1.0mg/dL). Other laboratory tests revealed
normal liver function, an HbA1c of 6.8%, free T4 level
of 0.76ng/dL (normal 0.89–1.76ng/dL), and a TSH level
of 5.9μIU/mL (0.34–4.82). A fasting lipid panel revealed a
total cholesterol level of 252mg/dL (normal <200mg/dL),
triglyceride level of 252mg/dL (normal 30–200mg/dL), high
density lipoprotein of 31mg/dL (normal 35–60mg/dL),
and a low density lipoprotein of 161mg/dL (normal 0–
120mg/dL). Her amylase was 74U/L and lipase was 100U/L,
both within the normal range. A urine drug screen was
positive for benzodiazepines; however, she was not cur-
rently prescribed any medications from this medication
class. The drug screen was negative for opioids, marijuana,
amphetamines, and cocaine. Blood cultures revealed no or-
ganism growth. Neither stool nor urine samples were taken.
An arterial blood gas was not drawn.
Initial treatment included sodium chloride 0.9% i.v.
ﬂuidsfordehydration,ondansetron8mgi.v.every4hoursas
needed for nausea and vomiting, as well as metoclopramide
10mg tablet before meals and at bedtime for abdominal
discomfort. Patient was kept without oral intake for one
day. She remained stable overnight with no additional
nausea, vomiting, or diarrhea. The following morning, she
received oral intake of food and liquids without feelings of
nausea or vomiting. Her white blood cell count was now
at 7,000cells/mm3 (normal 4.3–10,000cells/mm3). She was
then discharged to continue her home medications along
with ondansetron 4mg PO every 4–6 hours as needed for
nausea.
3. Discussion
The diﬀerential diagnosis included multiple factors prior to
the possible diagnosis of S. divinorum withdrawal. First was
a consideration for the possibility of a gastrointestinal virus
or food poisoning. The patient reported no sick contacts at
home, and she had not experienced fever. She also reported
that she had not eaten outside her home within the last
48 hours and she had not eaten anything outside of her
ordinary diet at home. Unfortunately stool and urine studies
studies were not obtained during her hospital stay making
it impossible to completely rule these out of the diﬀerential.
The patient had a noncontributory past medical history
and she reported no other pertinent ill contacts. Her labs
including the amylase and lipase were normal. The lipid
panel, triglycerides in particular, was slightly elevated but
not enough to suspect pancreatitis. Urine drug screening was
positive for benzodiazepines; however, it was negative for
all other substances reducing the possibility of side eﬀects
or withdrawal from other common illicit medications. She
did report smoking the herb S. divinorum consistently for
several months. She then reported discontinuing the use of
this product approximately 48 hours prior to onset of herCase Reports in Medicine 3
reported symptoms. This led to the inclusion of withdrawal
from this substance in the diﬀerential diagnosis. After close
observation and treatment with i.v. ﬂuids and antiemetics
she was released from the hospital.
The active ingredient of S. divinorum, Salvinorin A, is
a unique natural compound that is a highly potent and
selective full agonist of the kappa-opioid receptor [5, 6].
Salvinorin A is the only known substance in the Salv-
inorin chemical class with binding aﬃnity at the kappa-
opioid receptor [1, 5]. Salvinorin A is diﬀerent from other
hallucinogens such as LSD or mescaline because it has
no binding aﬃnity for the 5-HT2A receptor [1, 3, 5].
The kappa-opioid receptor is only found in the brain and
spinal cord and is commonly associated with analgesia,
sedation, inhibition of gastrointestinal transit, and general
dysphoria. The association between Salvinorin A stimulation
of the kappa-opioid receptor and hallucinations continues
to be elucidated. The lack of serotonergic properties makes
this agent unique among the other hallucinogens currently
popular [3]. Currently, management of Salvinorin A toxicity
includes supportive care only.
The unique opioid properties may explain its ability to
cause changes in intestinal transit time. A small amount
of literature is available linking Salvinorin A to eﬀects
seen in the gastrointestinal (GI) system. A study by Fichna
et al. looked at its eﬀects on GI transit in mice. When
given to mice, Salvinorin A inhibited cholinergic excitatory
neurotransmission, reducing GI motility. This activity had
antidiarrheal or constipating eﬀects [10]. Fichna et al.
continued to look into these eﬀects on GI motility in an
additional study. When Salvinorin A is given, cholinergic
and noncholinergic excitatory transmission is inhibited, thus
decreasing smooth muscle contraction in the GI tract [11].
Similar eﬀects have been also seen in guinea pigs [10, 11].
It is yet to be observed in clinical reports whether the GI
eﬀects of Salvinorin A also occur in humans with prolonged
or high amounts of use; however, these animal reports do
oﬀer some explanation as to why our patient may have
experiencedincreasedGImotilityandabdominaldiscomfort
upon withdrawal of Salvinorin A.
The diﬃculty in establishing reproducible cause and
eﬀect with a herbal product is due to the lack of standard-
ization amongst the Salvia divinorum products currently
available. The various products may vary as much as 50
fold in potency for actual mg of Salvia divinorum in the
product. The pharmaceutical delivery method may also
impact the potency delivered to the patient. The dosage form
is particularly pertinent in the case of the current patient
who was smoking the herb and inhaling it [12]. The half-
life of Salvia has been reported to range from 40 minutes
to 1.5 hours [3]. However, these characterizations of half-
life are based on single-dose pharmacokinetics. Descriptions
of the physiologic behaviour of this substance after chronic
use are not currently available in the literature. Variability
in pharmacokinetics may explain the delayed onset of
symptoms in this patient. Many of the opioid classes of
agents have varied lipophilicity and the onset of withdrawal
depends on half-life and the amount accumulated in fat
deposits [13].
4. Conclusion
A 51-year-old woman developed gastrointestinal manifesta-
tions suggestive of withdrawal from Salvia divinorum after
discontinuing her smoking of the substance consistently for
3 to 4 months. This may be the ﬁrst documented case
report of gastrointestinal symptoms of withdrawal from
this substance. Considering the increased popularity of this
herb, it would not be surprising to see similar reports of
withdrawalinthefuture.Duetothelackofroutinescreening
and the popularity of this herb, patients presenting with
similar symptoms and possible risks for drug abuse should
be screened for misuse of Salvia divinorum.
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